Viking Therapeutics, Inc. (NASDAQ:VKTX) is highlighted as one of the best oversold NASDAQ stocks to buy now. H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on VKTX with a price target of $102.00, causing the stock to soar 9.7%.

On June 25, Viking Therapeutics, Inc. (NASDAQ:VKTX) launched the VANQUISH Phase 3 clinical program for VK2735, a dual agonist aimed to treat metabolic disorders like obesity. The program includes studies on obese or overweight adults with type 2 diabetes and adults with obesity.

VK2375, under development by Viking Therapeutics, Inc. (NASDAQ:VKTX), is being considered for treating metabolic disorders through subcutaneous and oral formulations. VKTX is a clinical-stage company focused on developing therapies for metabolic and endocrine disorders.

Read more at Yahoo Finance: H.C. Wainwright Reiterates a Buy Rating on Viking Therapeutics (VKTX), Sets a $102 PT